Another Potential Boondoggle for "Big Pharma"?

This week a controversy has developed over a new set of guidelines published by the Amer.Heart Ass'n & College of Cardiology for lowering cholesterol along w/a calculator meant to assess risks. Two Harvard Med.Sch.Profs took issue w/the report w/ their data showing the calculator over predicting risk by 75 to 150% saying overestimation of risk will lead to considerable overprescription, (a potential boondoggle for Big Pharma).